Gujarat Themis Biosyn Limited (BOM:506879)

Market Cap	41.75B +24.4%
Revenue (ttm)	1.66B +10.0%
Net Income	466.82M -4.3%
EPS	4.28 -4.4%
Shares Out	108.97M
PE Ratio	89.52
Forward PE	n/a
Dividend	0.67 (0.17%)
Ex-Dividend Date	Sep 4, 2025

Volume	15,094
Open	381.40
Previous Close	381.35
Day's Range	368.90 - 386.00
52-Week Range	225.75 - 479.45
Beta	0.33
Analysts	Strong Buy
Price Target	6.27 (-98.32%)
Earnings Date	May 25, 2026

About Gujarat Themis Biosyn

Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O for the treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1981
• Employees: 221
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 506879

Financial Performance

In fiscal year 2026, Gujarat Themis Biosyn's revenue was 1.66 billion, an increase of 9.96% compared to the previous year's 1.51 billion. Earnings were 466.82 million, a decrease of -4.29%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 19, 2026

Data Sources Report a data error